@article{1a49900ff7ea450ba59325c4043d1fd4,
title = "Disseminated Mycobacterium massiliense infection in a patient with myelodysplastic syndrome undergoing allogeneic bone marrow transplantation",
abstract = "Nontuberculous mycobacteria are ubiquitous in water and soil, and the subset of rapidly growing mycobacteria species can cause severe infections in immunocompromised patients. Solid organ or hematopoietic stem cell transplantation (HSCT) recipients are known to be susceptible to infection by nontuberculous mycobacteria. The nontuberculous mycobacteria species Mycobacterium massiliense (M massiliense) has been classified as a rapidly growing mycobacteria and recognized as a pathogen causing lung and soft tissue infections in humans. However, there have been only a few reported cases of M massiliense infection after solid organ transplantation and HSCT. We herein report another case of M massiliense infection after allogeneic HSCT, which manifested as soft tissue infection, lung infection, and bacteremia.",
keywords = "Mycobacterium massiliense, allogeneic bone marrow transplantation, bacteremia, subcutaneous tissue infection",
author = "Takaaki Toyama and Takehiko Mori and Jun Kato and Kayoko Sugita and Naoki Hasegawa and Noboru Nakata and Yoshihiko Hoshino and Shinichiro Okamoto",
note = "Funding Information: Takehiko Mori received research funding from MSD, Novartis Pharma, LSI Medience, Medical & Biological Laboratories, and Asahi Kasei Corporation, and personal fees from Pfizer Inc, MSD, Janssen Pharma, Sumitomo Dainippon Pharma, Novartis Pharma, Kyowa Kirin, Chugai Pharmaceutical, Shionogi & Co., Japan Blood Products Organization, Takeda Pharmaceutical, Ono Pharmaceutical, Shire, Eisai, and Astellas Pharma; Jun Kato received personal fees from Astellas Pharma, Otsuka Pharmaceutical, Janssen Pharma, Pfizer, Takeda Pharmaceutical, JCR Pharmaceuticals; Naoki Hasegawa received personal fees and research funding from Pfizer Inc, MSD, Eisai, Daiichi Sankyo, Taisho Pharmaceutical, Sumitomo Dainippon Pharma, and Astellas Pharma, and a grant from Insmed Incorporated; Shinichiro Okamoto received research funding from Sumitomo Dainippon Pharma, Pfizer, Teijin Pharma, Novartis Pharma, Bristol‐Myers Squibb, Mochida Pharmaceutical, JCR Pharmaceuticals, Toyama Chemical, Takeda Pharmaceutical, Daiichi Sankyo, Shionogi & Co., Sanofi, Kyowa Kirin, Ono Pharmaceutical, Otsuka Pharmaceutical, Eisai, Asahi Kasei Corporation, and Japan Blood Products Organization, and personal fees from Pfizer, Janssen Pharma, and Astellas Pharma. Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2020",
month = jun,
day = "1",
doi = "10.1111/tid.13278",
language = "English",
volume = "22",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "3",
}
